Search Result

Results for "

CCK-B antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cholecystokinin Receptor (23) CCR (2) Endogenous Metabolite (1) Reference Standards (3)
By Research Areas:	Cancer (1) Endocrinology (2) Inflammation/Immunology (2) Metabolic Disease (13) Neurological Disease (10)

Inhibitors & Agonists

Peptides

Targets Recommended: Cholecystokinin Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14850

Sograzepide 1 Publications Verification Netazepide; YF 476; YM-220	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active *Gastrin/CCK-B* antagonist with an IC₅₀ value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC₅₀ of 502 nM . Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with K_i values of 0.068, 0.62 and 0.19 nM, respectively .

HY-106840

L-365260 2 Publications Verification	Cholecystokinin Receptor	Neurological Disease Metabolic Disease
L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .

HY-103355

YM022 2 Publications Verification	CCR	Metabolic Disease
YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the K_i values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .

HY-U00360

(Rac)-Sograzepide (Rac)-Netazepide; (Rac)-YF 476; (Rac)-YM-220	Cholecystokinin Receptor	Metabolic Disease
(Rac)-Sograzepide is an antagonist of cholecystokinin B *(CCK-B) receptor*, and has the potential of reducing the secretion of gastric acid.

HY-129357

CCK-B Receptor Antagonist 2	Cholecystokinin Receptor	Metabolic Disease
CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active *Gastrin/CCK-B* antagonist with an IC₅₀ value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC₅₀ of 1.82 μM .

HY-19261

T-0632	Cholecystokinin Receptor	Metabolic Disease
T-0632 is a CCK A receptor antagonist that exhibits significant pharmacological properties in in vitro studies. T-0632 competitively inhibits the binding of [125I]CCK-8 to rat pancreatic CCK A receptors with a K_i value of 0.24 nM, which is significantly lower than the K_i value for guinea pig CCK B receptors. T-0632 has higher selectivity in inhibiting CCK-8-stimulated pancreatic enzyme release, with an IC_50 value of 5.0 nM, which is more advantageous than L-364,718 and loxiglumide. In rabbit gallbladder smooth muscle, the antagonistic effects of T-0632 and loxiglumide are reversible, while L-364,718 shows a persistent inhibitory effect. These results indicate that T-0632 is a highly potent, reversible and more selective CCK A receptor antagonist.

HY-106840A

L-365260 hemihydrate 2 Publications Verification	Cholecystokinin Receptor	Neurological Disease Metabolic Disease
L-365260 hemihydrate is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 hemihydrate interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors .

HY-118194

A-65186	Cholecystokinin Receptor	Others
A-65186 is a CCK-A receptor antagonist with the activity of inhibiting CCK8-induced amylase secretion. A-65186 has high binding affinity for pancreatic CCK-A receptors, is more than 500 times more selective for CCK-A receptors than for CCK-B receptors, and can inhibit CCK8-induced amylase secretion.

HY-U00360R

(Rac)-Sograzepide (Standard) (Rac)-Netazepide (Standard); (Rac)-YF 476 (Standard); (Rac)-YM-220 (Standard)	Reference Standards Cholecystokinin Receptor	Metabolic Disease
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.

HY-103357A

LY262691	Cholecystokinin Receptor	Neurological Disease
LY262691 is a selective *CCK-B* antagonist with antipsychotic properties. LY262691 decreases the number of spontaneously active A9 and A10 dopamine cells and can be utilized in antipsychotic research .

HY-129810

PD 135158 CAM 1028	Cholecystokinin Receptor	Neurological Disease
PD 135158 (CAM 1028) is a selective *CCK_B* receptor antagonist with an IC₅₀ of 2.8 nM against mouse cortex CCK_B. PD 135158 shows anxiolytic activity .

HY-19290

S-0509	Cholecystokinin Receptor	Others
S-0509 is a selective *CCKB/gastrin* receptor antagonist. S-0509 has a strong anti-secretion effect. S-0509 helps prevent the occurrence of duodenal ulcers .

HY-106347

Itriglumide CR 2945	Cholecystokinin Receptor	Inflammation/Immunology
Itriglumide (CR 2945) is an anthranilic acid derivative. Itriglumide is a potent and selective CCKB receptor antagonist, with an IC₅₀ of 2.3 nM. Itriglumide antagonizes the response to gastrin in a dose-dependent manner with an IC₅₀ of 5.9 nM. Itriglumide shows antisecretory and antiulcer activity .

HY-118314

CI-1015 PD 144598	Cholecystokinin Receptor	Cancer
CI-1015 is a potent CCK-B receptor antagonist.

HY-106356

GV-150013	Cholecystokinin Receptor	Others
GV-150013 is a selective *CCK-B* receptor antagonist. GV-150013 has sleep aid effect .

HY-100481

RP 72540 RPR101048	Cholecystokinin Receptor	Neurological Disease
RP 72540 is a selective *CCK-B* receptor antagonist, with IC₅₀ values of 2.4, 1.2, and 3.8 nM for *CCK-B* receptors in the guinea pig cerebral cortex, rat cerebral cortex, and mouse brain, respectively. RP 72540 effectively inhibits *CCK-8*-induced neuronal firing and dose-dependently inhibits gastric acid secretion, making it potentially valuable in studies of acid secretion. RP 72540 is an important tool for investigating the physiological functions of CCK B receptors .

HY-103357

LY288513	Cholecystokinin Receptor	Neurological Disease
LY288513 is a selective non-peptide *CCK-B* receptor antagonist with an IC₅₀ value of 16 nM. LY288513 produces an anxiolytic-like action in mice .

HY-125610

DA-3934	Cholecystokinin Receptor	Neurological Disease
DA-3934 is a *cholecystokinin (CCK)-B* receptor** antagonist. DA-3934 inhibits Pentagastrin (HY-A0261)-induced gastric acid secretion in rats .

HY-118665

L-736380	Cholecystokinin Receptor	Metabolic Disease
L-736380 is a high affinity CCK-B (cholecystokinin B receptor) receptor antagonist, with IC₅₀ values of 0.054 nM and 400 nM for CCK-B and CCK-A, respectively. L-736380 dose-dependently inhibits gastric acid secretion in anesthetized rats (ID₅₀, 0.064 mg/kg) and ex vivo binding of [125I]CCK-8S in BKTO mice brain membranes (ED₅₀, 1.7 mg/kg) .

HY-P2055

A-57696	Endogenous Metabolite	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

HY-169139

Spiroglumide CR-2194	Cholecystokinin Receptor	Metabolic Disease
Spiroglumide (CR-2194) is a selective *cholecystokinin B (CCKB) receptor* antagonist .

HY-120862

L 368935	Cholecystokinin Receptor	Neurological Disease
L 368935 is a *cholecystokinin B receptor (CCKB* receptor)** antagonist. L 368935 is a brain-penetrant and centrally active compound .

HY-119127

TP-680	Cholecystokinin Receptor	Metabolic Disease
TP-680 is a cholecystokinin receptor antagonist. TP-680 binds 1510 times more strongly to rat pancreatic CCK_A receptors (IC₅₀=1.2 nM) than to rat brain *CCK_B* receptors (IC₅₀=1812.5 nM). TP-680 can be used in the study of gastrointestinal diseases .

HY-103355R

YM022 (Standard)	Reference Standards CCR	Metabolic Disease
YM022 (Standard) is the analytical standard of YM022 (HY-103355). This product is intended for research and analytical applications. YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the K_i values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .

HY-106840R

L-365260 (Standard)	Reference Standards Cholecystokinin Receptor	Neurological Disease Metabolic Disease
L-365260 (Standard) is the analytical standard of L-365260 (HY-106840). This product is intended for research and analytical applications. L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystoK_inin receptor (CCK-B), with K_is of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .

HY-116260

RP-69758	Cholecystokinin Receptor	Neurological Disease Inflammation/Immunology
RP-69758 is a potent and selective non-peptide cholecystokinin-B (CCK_B)/gastrin receptor antagonist. RP-69758 exhibits >200-fold selectivity for CCK_B over CCK_A receptors. RP-69758 antagonizes CCK-8-induced neuronal firing in rat hippocampal slices. RP-69758 inhibits Pentagastrin (HY-A0261)-induced gastric acid secretion in the rat. RP-69758 can be used for neurological disorders and gastrointestinal disease research .

Cat. No.	Product Name	Target	Research Area

HY-P2055

A-57696	Endogenous Metabolite	Endocrinology
A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.